clinical trial · NCT05296070
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
University of Miami·phase2·recruiting·n = 50
Marginal Zone LymphomaLoncastuximab tesirine 150 µg/KgLoncastuximab tesirine 75µg/Kg
brief summary
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
started
Jun 21, 2022
primary completion
Jun 30, 2028
completion
Jun 30, 2029
last updated
Sep 30, 2025
official title
A Phase 2, Open-label, Study Evaluating Safety and Efficacy of the Loncastuximab in Relapsed/Refractory Marginal Zone Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol